We are live on
!
Find out more
Celldex Therapeutics
CLDX
CLDX
197 hedge funds and large institutions have $2.91B invested in Celldex Therapeutics in 2024 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 81 increasing their positions, 43 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
262% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 13
88% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 43
20% more funds holding
Funds holding: 164 → 197 (+33)
19% more capital invested
Capital invested by funds: $2.44B → $2.91B (+$464M)
5.13% less ownership
Funds ownership: 112.72% → 107.59% (-5.1%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
59% less call options, than puts
Call options by funds: $9.84M | Put options by funds: $24M
Holders
197
Holders Change
+33
Holders Change %
+20.12%
% of All Funds
2.84%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.07%
New
47
Increased
81
Reduced
43
Closed
13
Calls
$9.84M
Puts
$24M
Net Calls
-$14.2M
Net Calls Change
-$5.86M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$110M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$109M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$48.1M |
| 4 |
BlackRock
New York
|
+$34.3M |
| 5 |
Jennison Associates
New York
|
+$27.4M |
Top Sellers
| 1 |
RI
RTW Investments
New York
|
-$137M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$60.5M |
| 3 |
Morgan Stanley
New York
|
-$38.6M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$30M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$28.1M |
